Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis
Breast Cancer Research and Treatment · 2026-06 · 217 (2)
DOI: 10.1007/s10549-026-07992-8 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 04.06.2026. Verfasst von Imad Barjij und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Institute of Oncology, Ibn Sina University Hospital, Rabat, Morocco. ibarjij@gmail.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoplasm, Residual, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Post-neoadjuvant circulating tumor DNA (ctDNA) has been investigated as a minimal residual disease (MRD) marker in stage I-III triple-negative breast cancer (TNBC), but landmark timing and assay approaches vary. OBJECTIVES: To assess whether post-neoadjuvant and/or peri-operative ctDNA MRD positivity is associated with poorer recurrence-related outcomes in TNBC with residual invasive disease, with overall survival evaluated as a secondary outcome and the association between ctDNA and pathologic complete response (pCR) assessed exploratorily. METHODS: PubMed/MEDLINE, Embase, Web of Science Core Collection, and Scopus were searched through January 15, 2026. Eligible studies enrolled adults with TNBC treated with neoadjuvant systemic therapy and surgery and reported post-neoadjuvant or peri-operative ctDNA with time-to-event outcomes; recurrence-related quantitative syntheses focused on residual invasive disease or extractable non-pCR/residual cancer burden (RCB) subgroups. Risk of bias was assessed using QUIPS. Random-effects meta-analysis was performed when studies were comparable; otherwise, findings were summarized narratively. RESULTS: Twenty-two studies were included. Four studies contributed to the primary meta-analysis. Post-treatment ctDNA positivity was associated with poorer recurrence-related outcomes (pooled hazard ratio 4.63, 95% CI 3.07-6.98; I²=0%), although this estimate should be interpreted cautiously given the small number of contributing studies. Overall survival could not be synthesized quantitatively. Two studies assessed the ctDNA-pCR association, but results were summarized narratively because TNBC-specific data were not extractable in one study. CONCLUSION: In TNBC patients with residual invasive disease or extractable non-pCR/RCB subgroup data after neoadjuvant therapy, post-neoadjuvant and peri-operative ctDNA MRD positivity is associated with poorer recurrence-related outcomes, supporting further standardized prospective evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Institute of Oncology, Ibn Sina University Hospital, Rabat, Morocco. ibarjij@gmail.com.
- Faculty of Medicine and Pharmacy of Rabat, Mohammed V University of Rabat, Rabat, Morocco. ibarjij@gmail.com.
- Department of Medical Oncology, National Institute of Oncology, Ibn Sina University Hospital, Rabat, Morocco.
- Faculty of Medicine and Pharmacy of Rabat, Mohammed V University of Rabat, Rabat, Morocco.
- Department of Medical Oncology, Tangier Regional Hospital Center, Tangier, Morocco.
Zitieren
APA
Barjij, I., Naciri, S., Lkhoyaali, S., Kharmoum, S., Inrhaouen, H., Elghissassi, I., Boutayeb, S., Mrabti, H., & Errihani, H. (2026). Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 217(2). https://doi.org/10.1007/s10549-026-07992-8
Vancouver
Barjij I, Naciri S, Lkhoyaali S, Kharmoum S, Inrhaouen H, Elghissassi I, et al. Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 2026;217(2). doi:10.1007/s10549-026-07992-8
BibTeX
@article{Barjij2026,
author = {Barjij, Imad and Naciri, Sarah and Lkhoyaali, Sihame and Kharmoum, Saoussane and Inrhaouen, Hanane and Elghissassi, Ibrahim and Boutayeb, Saber and Mrabti, Hind and Errihani, Hassan},
title = {Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis},
journal = {Breast Cancer Research and Treatment},
year = {2026},
volume = {217},
number = {2},
doi = {10.1007/s10549-026-07992-8}
}
EUVIMED